RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization
Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027
Read more at globenewswire.comRenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization
Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027
Read more at globenewswire.comContact Us
Contact Number :+852 3852 8500
English